Please find the ROE, RNOA, NOPM, NOAT, AT, ROA, Times Interest Earned, Cash Flow from Operations to Total Debt, Free Cash Flow to Total Debt, Current Ratio, Quick Ratio, Liabilities to Equity Ratio, Total Debt to Equity Ratio, Turnover Ratios for Cash, A/R, Inventory, and A/P, and Z-Score for all years. Also, please show work!

Consolidated Balance Sheet - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current Assets
Cash and cash equivalents	$ 8,524	$ 7,441	$15,621	$13,451
Short-term investments	4,903	8,278	1,865	2,690
Accounts receivable (net of allowance for doubtful accounts of $165 in 2015 and $153 in 2014) (excludes accounts receivable of $10 in 2015 and $80 in 2014 classified in Other assets - see Note 5)	6,484	6,626	7,184	7,672
Inventories (excludes inventories of $1,569 in 2015 and $1,664 in 2014 classified in Other assets - see Note 6)	4,700	5,571	6,226	6,535
Other current assets	5,153	4,689	0	0
Deferred income taxes and other current assets	0	0	4,789	4,509
Total current assets	29,764	32,605	35,685	34,857
Investments	13,039	13,515	9,770	7,305
Property, Plant and Equipment (at cost)
Land	490	541	550	591
Buildings	12,154	13,101	13,627	13,196
Machinery, equipment and office furnishings	14,261	16,050	17,106	17,188
Construction in progress	1,525	1,448	1,811	2,440
Property, Plant and Equipment, Gross	28,430	31,140	33,094	33,415
Less: accumulated depreciation	15,923	18,004	18,121	17,385
Property, Plant and Equipment, Net, Total	12,507	13,136	14,973	16,030
Goodwill	17,723	12,992	12,301	12,134
Other Intangibles, Net	22,602	20,386	23,801	29,083
Other Assets	6,144	5,533	9,115	6,723
Total Assets	101,779	98,167	105,645	106,132
Current Liabilities
Loans payable and current portion of long-term debt	2,585	2,704	4,521	4,315
Trade accounts payable	2,533	2,625	2,274	1,753
Accrued and other current liabilities	11,216	10,523	9,501	9,737
Income taxes payable	1,560	1,237	251	1,200
Dividends payable	1,309	1,308	1,321	1,343
Total current liabilities	19,203	18,397	17,868	18,348
Long-Term Debt	23,929	18,699	20,539	16,254
Deferred Income Taxes and Other Noncurrent Liabilities	13880	12,079	14,912	16,067
Merck & Co., Inc. Stockholders Equity
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2015 and 2014	1,788	1,788	1,788	1,788
Other paid-in capital	40,222	40,423	40,508	40,646
Retained earnings	45,348	46,021	39,257	39,985
Accumulated other comprehensive loss	(4,148)	(4,323)	-2,197	-4,682
Stockholders' equity before deduction for treasury stock	83,210	83,909	79,356	77,737
Less treasury stock, at cost: 795,975,449 shares in 2015 and 738,963,326 shares in 2014	38,534	35,262	29,591	24,717
Total Merck & Co., Inc. stockholders equity	44,676	48,647	49,765	53,020
Noncontrolling Interests	91	144	2,561	2,443
Total equity	44,767	48,791	52,326	55,463
Total Liabilities and Equity	$ 101,779	$ 98,167	$105,645	$106,132

Consolidated Statement of Income - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Sales	$ 39,498	$ 42,237	$ 44,033	$47,267
Costs, Expenses and Other
Materials and production	14,934	16,768	16,954	16,446
Marketing and administrative	10,313	11,606	11,911	12,776
Research and development	6,704	7,180	7,503	8,168
Restructuring costs	619	1,013	1,709	664
Equity income from affiliates	0	0	0	-642
Other (income) expense, net	1,527	(11,613)	411	1,116
Total Costs, Expenses and Other	34,097	24,954	38,488	38,528
Income Before Taxes	5,401	17,283	5,545	8,739
Taxes on Income	942	5,349	1,028	2,440
Net Income	4,459	11,934	4,517	6,299
Less: Net Income Attributable to Noncontrolling Interests	17	14	113	131
Net Income Attributable to Merck & Co., Inc.	$ 4,442	$ 11,920	$ 4,404	$6,168
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	$ 1.58	$ 4.12	$ 1.49	$2.03
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	$ 1.56	$ 4.07	$ 1.47	$2

Consolidated Statement of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash Flows from Operating Activities
Net income	$ 4,459	$ 11,934	$ 4,517	$6,299
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	6,375	6,691	6,988	6,978
Intangible asset impairment charges	162	1,222	765	200
Foreign currency devaluation related to Venezuela	876	0	140	0
Net charge related to the settlement of Vioxx shareholder class action litigation	680	0	0	0
Gain on divestiture of Merck Consumer Care business	0	(11,209)	0	0
Gain on AstraZeneca option exercise	0	(741)	0	0
Loss on extinguishment of debt	0	628	0	0
Equity income from affiliates	(205)	(257)	(404)	-642
Dividends and distributions from equity method affiliates	50	185	237	291
Deferred income taxes	(764)	(2,600)	(330)	669
Share-based compensation	299	278	276	335
Other	757	(95)	259	28
Net changes in assets and liabilities:
Accounts receivable	(480)	(554)	436	349
Inventories	805	79	(365)	-482
Trade accounts payable	(37)	593	522	-302
Accrued and other current liabilities	(8)	1,635	(397)	-717
Income taxes payable	(266)	(21)	(1,421)	-34
Noncurrent liabilities	(277)	190	(132)	-1,747
Other	(5)	(98)	563	-1,203
Net Cash Provided by Operating Activities	12,421	7,860	11,654	10,022
Cash Flows from Investing Activities
Capital expenditures	(1,283)	(1,317)	(1,548)	-1,954
Purchases of securities and other investments	(16,681)	(24,944)	(17,991)	-12,841
Proceeds from sales of securities and other investments	20,413	15,114	16,298	7,783
Divestiture of Merck Consumer Care business, net of cash divested	0	13,951	0	0
Dispositions of other businesses, net of cash divested	316	1,169	46	0
Proceeds from AstraZeneca option exercise	0	419	0	0
Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired	(7,598)	0	0	0
Acquisition of Idenix Pharmaceuticals, Inc., net of cash acquired	0	(3,700)	0	0
Acquisitions of other businesses, net of cash acquired	(146)	(181)	(246)	0
Acquisition of Bayer AG collaboration rights	0	(1,000)	0	0
Cash inflows from net investment hedges	139	195	350	39
Other	82	(80)	(57)	168
Net Cash Used in Investing Activities	(4,758)	(374)	(3,148)	-6,805
Cash Flows from Financing Activities
Net change in short-term borrowings	(1,540)	(460)	(159)	624
Payments on debt	(2,906)	(6,617)	(1,775)	-22
Proceeds from issuance of debt	7,938	3,146	6,467	2,562
Purchases of treasury stock	(4,186)	(7,703)	(6,516)	-2,591
Dividends paid to stockholders	(5,117)	(5,170)	(5,157)	-5,116
Other dividends paid	0	(77)	(120)	-120
Proceeds from exercise of stock options	485	1,560	1,210	1,310
Other	56	208	60	86
Net Cash Used in Financing Activities	(5,270)	(15,113)	(5,990)	-3,267
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(1,310)	(553)	(346)	-30
Net Increase (Decrease) in Cash and Cash Equivalents	1,083	(8,180)	2,170	-80
Cash and Cash Equivalents at Beginning of Year	7,441	15,621	13,451	13,531
Cash and Cash Equivalents at End of Year	$ 8,524	$ 7,441	$ 15,621	$13,451